KERREY J ROBERT sold (to issuer) $105K of THC

KERREY J ROBERT sold (to issuer) 607 shares of TENET HEALTHCARE CORP (THC) at $173.78 ($0.11M total) on 2026-05-22.

Original reporting
SEC EDGAR · KERREY J ROBERT
Published May 27, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
high confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

Because the disclosure is limited to share count, price, and a sale-to-issuer code (D), it does not provide new operational or financial information.

02

Market read

A disclosed insider sale to the issuer is typically low-signal; traders may only react if it contributes to a broader insider-selling trend.

03

What to watch

Assess whether there’s a pattern of director/officer selling across recent Form 4s; one-off sales are often non-informative.

Relevance 6/10Timing: Filed 2026-05-26 for a 2026-05-22 transaction; any trading impact would be limited to the disclosure window.

Background

The filing is an SEC Form 4 insider transaction for Tenet Healthcare (THC), reporting a director sale to the issuer on 2026-05-22.

Company-level read

Ticker impact

$THCNeutralHigh confidence
Context

Tenet Healthcare director Kerrey J. Robert sold 607 shares to the issuer for about $105.5K at $173.78/share, per SEC Form 4.

Expected impact

Minimal near-term impact; any move is more likely noise unless repeated insider selling accelerates.

Evidence & confidence

Single small director transaction disclosed via Form 4, with no earnings/guidance/transaction details beyond the sale code and price.

Market effects

No direct sector read-across; insider Form 4s generally don’t reset healthcare/managed-care expectations.

None indicated.

None indicated.

Counterpoint

If insider sales to the issuer are part of a broader buyback program, the transaction may reflect liquidity/plan mechanics rather than negative views.

Key entities

  • TENET HEALTHCARE CORP

    Subject of the Form 4 insider transaction; director Kerrey J. Robert sold 607 shares to the issuer.

  • KERREY J ROBERT

    Director who sold shares to the issuer; holdings after transaction were 22,442 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.